Drug Trial Radar · NCT02476006
Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)
Last checked: Nov 20, 2026Latest source record: Mar 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
998
Actual
Start
Jun 23, 2015
Primary completion
Apr 12, 2019
Study completion Apr 12, 2019
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- Regeneron Pharmaceuticals
- First posted
- Jun 19, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: To provide participants with severe hypercholesterolemia at risk for subsequent cardiovascular (CV) events and not adequately controlled with currently available lipid-modifying therapy (LMT) access to alirocumab ahead of commercial availability and to document the overall safety and tolerability of alirocumab in this participant population. Secondary Objectives: To document the effect of alirocumab on low-density lipoprotein cholesterol (LDL-C) levels as well as non-high-density lipoprotein cholesterol (non-HDL-C), total cholesterol (total-C), high-density lipoprotein cholesterol (HDL-C), and triglyceride (TG) levels after 12 weeks of treatment. To document participant's acceptability of self-injection (Self Injection Assessment Questionnaire, SIAQ).
Conditions
- Hypercholesterolemia
Interventions
ALIROCUMAB SAR236553 (REGN727)Drug
Pharmaceutical form:solution Route of administration: subcutaneous
placebo (for injection training only)Drug
Pharmaceutical form:solution Route of administration: subcutaneous
ezetimibeDrug
Pharmaceutical form:capsule Route of administration: oral
atorvastatinDrug
Pharmaceutical form:tablet Route of administration: oral
rosuvastatinDrug
Pharmaceutical form:tablet Route of administration: oral
simvastatinDrug
Pharmaceutical form:tablet Route of administration: oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: From first injection of investigational medicinal product (IMP) up to 2 weeks after last dose of study drug (Week 120)
Locations
153 sites in 16 countries. Site status is shown where the registry gives one.
Investigational Site Number 040001
Graz, Austria
Investigational Site Number 040008
Innsbruck, Austria
Investigational Site Number 040005
Linz, Austria
Investigational Site Number 040006
Linz, Austria
Investigational Site Number 040003
Vienna, Austria
Investigational Site Number 040002
Vienna, Austria
Investigational Site Number 040004
Vienna, Austria
Investigational Site Number 040007
Vienna, Austria
Investigational Site Number 040010
Vienna, Austria
Investigational Site Number 056005
Aalst, Belgium
Investigational Site Number 056018
Antwerp, Belgium
Investigational Site Number 056008
Arlon, Belgium
Investigational Site Number 056013
Bruges, Belgium
Investigational Site Number 056010
Brussels, Belgium
Investigational Site Number 056003
Brussels, Belgium
Investigational Site Number 056006
Charleroi, Belgium
Investigational Site Number 056007
Edegem, Belgium
Investigational Site Number 056019
Genk, Belgium
Investigational Site Number 056001
Ghent, Belgium
Investigational Site Number 056017
Ghent, Belgium
Investigational Site Number 056002
Haine-Saint-Paul, Belgium
Investigational Site Number 056015
Kortrijk, Belgium
Investigational Site Number 056009
La Louvière, Belgium
Investigational Site Number 056004
Leuven, Belgium
Investigational Site Number 056014
Liège, Belgium
Investigational Site Number 056011
Overpelt, Belgium
Investigational Site Number 056016
Roeselare, Belgium
Investigational Site Number 124018
Calgary, Canada
Investigational Site Number 124015
Cambridge, Canada
Investigational Site Number 124002
Chicoutimi, Canada
Investigational Site Number 124027
Coquitlam, Canada
Investigational Site Number 124025
Edmonton, Canada
Investigational Site Number 124017
Halifax, Canada
Investigational Site Number 124013
Hamilton, Canada
Investigational Site Number 124008
London, Canada
Investigational Site Number 124026
Maple Ridge, Canada
Investigational Site Number 124020
Montreal, Canada
Investigational Site Number 124022
Montreal, Canada
Investigational Site Number 124032
Mount Pearl, Canada
Investigational Site Number 124005
Ottawa, Canada
Showing 40 of 153 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.